Immune Response in Lung Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01955343

Acronym

IRLC

Enrollment

100

Registered

2013-10-07

Start date

2012-09-30

Completion date

2016-03-31

Last updated

2017-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Keywords

Immune response, Cancer

Brief summary

This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Eastern Cooperative Oncology Group (ECOG) score of 0-1 * Patients with histologically documented non-small cell lung cancer * Control group - patients without non-small cell lung cancer * Written (signed) Informed Consent to participate in the study

Exclusion criteria

* Any other malignancies within 5 years * Any unstable systemic disease (including active infections, significant cardiovascular disease) * Prior chemotherapy or radiotherapy * Autoimmune disease * Nursing or pregnant women

Design outcomes

Primary

Measure	Time frame
progression-free survival	one year after enrolment to the study

Secondary

Measure	Time frame
overall survival	3 years

Countries

Lithuania

Outcome results